Fig. 6: Treatment with iGN improves survival of tumor-bearing mice.
From: Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy
a Experimental schedule for evaluating a combination therapy using iGN and anti-PD-1 (αPD-1) antibodies. EG7-OVA cells (5 × 105) were subcutaneously (s.c.) transplanted into the right flank on the back of C57BL/6 mice. Five days after transplantation, the mice were injected with PBS or iGN (0.4 nmol 1V209/injection) at the base of the tail thrice every 3 days (at days 5, 8, and 11). Anti-PD-1 antibodies (100 μg/mouse) were intraperitoneally administered (or not administered) on days 7 and 11. b Kaplan–Meier survival curves of mice treated with PBS, αPD-1 antibodies, iGN, or iGN in combination with anti-PD-1 antibodies. n = 12 mice for PBS and αPD-1 antibodies group; n = 13 mice for iGN and iGN + αPD-1 group. ***p < 0.001, log-rank test.
